Skip to main content
Premium Trial:

Request an Annual Quote

Helomics GeneFx Colon

Helomics announced today the official launch of GeneFx Colon, its multi-gene expression assay designed to identify colon cancer patients who are at a higher risk of recurrence within five years following initial surgery. The test is intended to help physicians make informed personalized treatment decisions about potentially adding adjuvant chemotherapy.

GeneFx Colon is performed on a small amount of tumor tissue and test results are available within the average time period for recovery post-surgery. The assay produces a binary result that categorizes patients as being at either high- or low-risk for a tumor recurrence within five years.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.